In the preceding three months, 9 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Janux Therapeutics, revealing an average target of $68.89, a high estimate of $100.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 85.19% from the previous average price target of $37.20.
Decoding Analyst Ratings: A Detailed Look
The standing of Janux Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $63.00 | $50.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $100.00 | - |
| Robert Driscoll | Wedbush | Raises | Outperform | $74.00 | $53.00 |
| Soumit Roy | JonesTrading | Announces | Buy | $70.00 | - |
| Kaveri Pohlman | BTIG | Announces | Buy | $62.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Announces | Overweight | $100.00 | - |
| Geoff Meacham | B of A Securities | Raises | Buy | $48.00 | $24.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $50.00 | $35.00 |
| David Driscoll | Wedbush | Raises | Outperform | $53.00 | $24.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Janux Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Janux Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Janux Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Janux Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Janux Therapeutics analyst ratings.
Get to Know Janux Therapeutics Better
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Key Indicators: Janux Therapeutics's Financial Health
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, Janux Therapeutics faced challenges, resulting in a decline of approximately -13.5% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Janux Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -477.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Janux Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.39%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Janux Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.